Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers.

To identify new biomarkers that improve the early diagnosis and lead to possible therapeutic targets in pancreatic carcinoma, we performed a proteomic approach to compare serum protein expression patterns of pancreatic carcinoma patients with that of gastric cancer patients, other pancreatic disease patients, and healthy volunteers. By two-dimensional gel electrophoresis (2-DE) analyses and mass spectroscopic identification, 10 protein spots were found significantly changed in pancreatic carcinoma and 5 proteins including cyclin I, Rab GDP dissociation inhibitor beta (GDI2), alpha-1 antitrypsin precursor, Haptoglobin precursor, and Serotransferrin precursor were successfully identified. The increased levels of cyclin I and GDI2 found to be associated with pancreatic carcinoma were further confirmed by Western blot analyses in an independent series of serum samples and/or pancreatic juice samples. Applying immunohistochemistry, we further validated expression of cyclin I and GDI2 in additional pancreatic carcinomas. These results indicate that cyclin I and GDI2 may be potential molecular targets for pancreatic cancer diagnostics and therapeutics.

IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils.

Allergic inflammation is characterized by elevated eosinophil numbers and by the increased production of the cytokines IL-5 and GM-CSF, which control several eosinophil functions, including the suppression of apoptosis. The JAK/STAT pathway is important for several functions in hemopoietic cells, including the suppression of apoptosis. We report in this study that STAT3, STAT5a, and STAT5b are expressed in human eosinophils and that their signaling pathways are active following IL-5 or GM-CSF treatment. However, in airway eosinophils, the phosphorylation of STAT5 by IL-5 is reduced, an event that may be related to the reduced expression of the IL-5Ralpha on airway eosinophils. Furthermore, IL-5 and GM-CSF induced the protein expression of cyclin D3 and the kinase Pim-1, both of which are regulated by STAT-dependent processes in some cell systems. Pim-1 is more abundantly expressed in airway eosinophils than in blood eosinophils. Because Pim-1 reportedly has a role in the modulation of apoptosis, these results suggest that Pim-1 action is linked to the suppression of eosinophil apoptosis by these cytokines. Although cyclin D3 is known to be critical for cell cycle progression, eosinophils are terminally differentiated cells that do not proceed through the cell cycle. Thus, this apparent cytokine regulation of cyclin D3 suggests that there is an alternative role(s) for cyclin D3 in eosinophil biology.

p21Cip1 levels differentially regulate turnover of mature endothelial cells, endothelial progenitor cells, and in vivo neovascularization.

p21(Cip1) (p21) controls cell cycle progression and apoptosis in mature endothelial cells (ECs) and regulates size and cycling of the hematopoietic progenitor cell pool. Because circulating endothelial progenitor cells (EPCs) contribute to postnatal neovascularization in addition to mature ECs, we investigated the regulation of ECs and EPCs in p21-deficient mice. Mature aortic EC proliferation was increased in homozygous p21(-/-) and heterozygous p21(+/-) mice, in which p21 protein levels are reduced to one third of wild-type (WT). In contrast, apoptosis sensitivity was increased by 3.5-fold only in p21(-/-), but not in p21(+/-) mice. Consistently, in vivo apoptosis of ECs within areas of neovascularization was elevated in p21(-/-) but not in p21(+/-) mice. EPC numbers were elevated 2-fold in p21(-/-) mice compared with WT (P<0.001), and clonal expansion capacity of EPCs was increased from 25+/-4 (WT) to 57+/-8 colony-forming units in p21(-/-) mice (P<0.005). EPC numbers and expansion were likewise increased in p21(+/-) mice. As the integrative endpoint, in vivo neovascularization reflecting all p21-affected parameters was increased over WT only in p21(+/-) (P<0.001), but not in p21(-/-) mice. In conclusion, reduced p21 protein levels of mice lacking one p21 allele are associated with increased proliferation of ECs and EPCs, whereas survival of ECs to apoptotic stimuli in vitro and in vivo is not impaired. Under these conditions, neovascularization was increased. In contrast, complete p21 deficiency did not result in an increased neovascularization despite increased mature EC and EPC proliferation. This may be due to the sensitization of ECs against apoptosis.

The influence of occupational exposure to PAHs on the blood plasma levels of p53 and p21WAF1 proteins.

Polycyclic aromatic hydrocarbons (PAHs) are the main source of carcinogenic risk among coke-oven workers. p53 is a tumor suppressor protein that is induced after DNA damage. It regulates the transcription of genes responsible for cell cycle arrest and apoptosis. p21(WAF1) protein is a downstream effector of p53; it induces cell cycle arrest either in the G(1), S, or G(2) phases. It has been shown that carcinogenic PAHs are able to induce the expression of both p53 and p21(WAF1) proteins in vitro. The purpose of the present study was to evaluate the effect of occupational exposure to carcinogenic PAHs on the level of p53 and p21(WAF1) proteins in blood plasma. The exposed group consisted of 66 coke-oven workers (males, average age 41 years, 42% smokers, 58% nonsmokers); the control group consisted of 49 machine workers (males, average age 49 years, 51% smokers, 49% nonsmokers). No difference in the plasma levels of either p53 (using anti-p53 antibody identifying both the mutated and the wild-type form of the protein) or p21(WAF1) protein was found between the exposed and control groups. Smoking had no effect on the levels of either protein in any of the analyzed groups. After stratification of all the subjects into groups according to their exposure to carcinogenic PAHs, a significantly higher level of p53 was found in the group exposed to carcinogenic PAHs <1 microg/m(3) as compared with the group exposed to carcinogenic PAHs >1 microg/m(3). A similar trend was observed for p21(WAF1) protein, even if no correlation between the levels of both proteins was detected. In the overall study a negative correlation between the levels of p53 protein and personal exposure to carcinogenic PAHs was found. These results did not support the expected response. The use of p53 as well as p21(WAF1) protein plasma levels as biomarkers of carcinogenic PAHs exposure requires further studies.

Differential gene expression in the activation and maturation of human monocytes.

Differential-display or RNA fingerprint was applied to identify genes differentially expressed in monocyte maturation induced by an immunomodulating peptide on human peripheral blood mononuclear cells. Two unknown sequences (06c22 and 06c71) and p21 protein (cyclin dependent kinase inhibitor) were repressed, and three genes activated: Cathepsin D, DRP2 (dihydropirimidinase related protein 2), and gp91phox (91-kDa subunit of citochrome b(558)). Phenotype of evolving monocytes was analyzed by flow cytometry and mRNA level of identified genes determined by reverse transcription-PCR. The expression pattern of identified genes seemed to correlate with different monocyte subsets, monocyte-derived cells, and expected functional changes. After peptide addition, immature monocytes were initially activated, increasing the expression of CD25, CD69, and HLA-DR markers. This was accompanied by repression of p21 and the two unknown sequences, along with the simultaneous activation of Cathepsin D and DRP2. Later, the differentiation marker CD16 rose, and gp91phox gene expression activated. Further maturation led certain monocytes to express marker CD23 and gp91phox expression to reach a maximum, while Cathepsin D and DRP2 dropped to preactivation levels. Results reflect part of the evolution of immature monocytes toward macrophages and monocyte-derived dendritic cell precursors.

[Expression and role of cyclin D3 in childhood acute leukemia].

OBJECTIVE: To investigate the expression and role of cyclin D in childhood acute leukemia(AL). METHODS: Immunohistochemistry was used to detect the expression of cyclin D1, D2, D3 in 43 samples of childhood AL patients and three leukemic cell lines. Cyclin D3 antisense oligodeoxynucleotides were used in in vitro culture study. RESULTS: Cyclin D3 expression was positive in 47% (14/30) of the childhood acute lymphoblastic leukemia and 38% (5/13) of the acute myelogenous leukemia patients and in CEM cells. Cyclin D1 was overexpressed in 5% (2/43) of the AL patients. No overexpression of cyclin D2 was detected. Incubation of CEM cells with cyclin D3 antisense oligodeoxynucleotides resulted in inhibition of cell proliferation. CONCLUSION: Cyclin D3 was overexpressed in childhood AL and it played an important role in the proliferation of leukemic cells.

[Prognostic value of molecular biologogy and immunologic parameters in human pancreatic carcinoma]. / Prognostische Wertigkeit molekularbiologischer und immunologischer Parameter beim humanen Pankreaskarzinom.

In the present study we investigated the prognostic relevance of molecular and immunological changes in pancreatic carcinoma. 82 tissue specimens of adenocarcinoma of the pancreas were stained immunohistochemically with following factors: p53, p21WAF1, Cyklin D, EGF, EGF-R, cERB-B2, CD95, BCL-2 and Cathepsin D. We further determined the serum levels of sCD44, sCD44v6, neopterin and IL-2R. Except Cyclin D none of the immunohistochemically determined factors had prognostic significance. Interestingly all of the immunological serum parameters were of high prognostic significance. These data demonstrate the prognostic relevance of immunological parameters in human adenocarcinoma of the pancreas and could raise the possibility of an early immunological intervention in pancreatic cancer.

Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers.

OBJECTIVES: The p21(WAF1/CIP1) cyclin-dependent kinase inhibitor is an Mr 21,000 protein that can arrest cell growth by associating with and inhibiting cyclin-dependent kinase complexes necessary for cells to exit G1. It is a downstream effector in the p53 growth control pathway and can be transcriptionally activated by increasing levels of p53 protein. The objective of this study was to determine if there are mutations or alterations in the expression of p21 in renal cancers that could contribute to renal cancer cell growth. METHODS: Twelve renal cancer cell lines were examined for mutations in the coding region of the p21 gene using single-stranded conformation polymorphism analysis and direct deoxyribonucleic acid (DNA) sequencing. Expression of p21 was determined in all 12 cell lines by Northern analysis using a cDNA probe for p21 and Western analyses using a p21-specific antibody. RESULTS: Nucleotide base substitutions were detected in the p21 gene in two cell lines, which did not result in amino acid substitutions. P21-specific mRNA was present in 8 of 12 renal cancer cell lines, as determined by Northern analysis, although p21 transcripts could be detected by polymerase chain reaction in all 12 renal cancers. Varying levels of p21-specific protein were detected in 9 of 12 renal cancers. CONCLUSIONS: These data indicate that mutation of the p21 gene is rare in renal cancer cell lines and that the uncontrolled growth of renal cancer cells is not due to mutation of the p21 gene. However, expression studies found a wide variation in the level of p21 protein in renal cancer cells, suggesting that aberrant regulation of p21 expression may play a role in renal cancer development.

Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma.

In mantle cell lymphoma, the t(11;14)(q13;q32) and its molecular counterpart, bcl-1 rearrangement, are consistent features and lead to cyclin D1 (bcl-1, PRAD1) proto-oncogene overexpression. In order to detect cyclin D1 overexpression, we developed a simple assay involving a reverse transcription followed by competitive polymerase chain reaction (PCR). A single upstream primer was derived from a homologous region between cyclin D1 and the other D-type cyclins, cyclins D2 and D3, while three downstream primers were specific to their respective D-type cyclins. Because the upstream primer was shared in PCR amplification of the three sequences, each PCR product served as a competitor and the quantification of the target was made by comparison of the intensity of the three products. With this assay we analyzed 45 hematopoietic cell lines and 40 clinical specimens. Cyclin D1 was rarely expressed in lymphoid cell lines except in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma, which expressed cyclin D1 predominantly. In myeloid cell lines, the levels of cyclin D1 expression varied and never exceeded the sum of cyclin D2 and D3 levels. Cyclin D3 was ubiquitously expressed while cyclins D1 and D2 were differentially used. The observations suggest that human cyclin D3 may play a fundamental role in hematopoiesis and that cyclins D1 and D2 may have different lineage- or differentiation-dependent functions. With this assay, small aliquots of clinical specimens such as 100 microL peripheral blood were enough to detect cyclin D1 overexpression without a well-controlled standard. The technique was validated as highly comparable with Northern analysis. This rapid and reliable detection of cyclin D1 overexpression may have practical clinical utility in the analysis and management of B-cell malignancies.